Condition: High Risk Prostate Cancer · Sponsor: Center Eugene Marquis
The aim of this clinical trial is to evaluate the efficacy of adaptive prostate Stereotatic Body RadioTherapy (SBRT), which integrates both Whole Pelvic RadioTherapy (WPRT) and dose escalation on the Dominant Intraprostatic Lesion (DIL), compared with standard radiotherapy. This will be assessed using a 5-year cost-utility analysis based on data from the clinical trial and the National Health Data System (NHDS).
This description comes directly from the study's public registry record.
Jennifer LE GUEVELOU, DR · 0299253000 · jennifer.leguevelou@gmail.com
Renaud DE CREVOISIER, PR · 0299253000 · r.de-crevoisier@rennes.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Eugène Marquis | Rennes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07189598